Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

NextCure, Inc.

NXTC · Nasdaq · CIK 0001661059 · Healthcare · Biotechnology

INSIDER SIGNAL

51.5 / 100

1 buyers · 12 purchase transaction lines · $1.6M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+19.0 / 25
Role+14.0 / 20
Recency+2.6 / 10
Conviction+8.8 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: TenPercentOwner (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: ADAR1 Capital Management, LLC; Schneeberger Daniel · $1.6M
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-07-27–2026-07-31

Roles in the peak window: TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
ADAR1 Capital Management, LLC; Schneeberger DanielTenPercentOwner
●●●●●
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.; Ren Jinsheng; Simcere Pharmaceutical Group Ltd; Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Zaiming, Inc.; Tang RenhongOther
▼
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

51.5 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 51.8
  2. 51.7
  3. 51.6
  4. 51.5
  5. 51.5

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

12Purchases
1Sales
0Other Form 4 lines
3SEC filings · 365 days
BUYING12 qualifying P line(s) · 180 days
SELLING1 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-1.8%
3M
+229.4%
6M
-38.3%
12M
+4.8%

Volatility & liquidity

Volatility
181.8%
Beta
—
Avg daily value
USD 15.4M

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-159.8%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
213,309
Previous report
105,240
Avg daily volume
114,775
Days to cover
1.9

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-31ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock36,303USD 4.94USD 179,348SEC filing ↗
2026-07-30ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock272,850USD 4.93USD 1,344,886SEC filing ↗
2026-07-29ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock3,410USD 5.00USD 17,050SEC filing ↗
2026-07-28ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock6,400USD 4.95USD 31,680SEC filing ↗
2026-07-27ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock7,798USD 5.00USD 38,990SEC filing ↗

Form 4 evidence

13 transaction lines in the latest 365-day window; 14 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-10Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.; Ren Jinsheng; Simcere Pharmaceutical Group Ltd; Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Zaiming, Inc.; Tang RenhongSale (S)Common Stock30,000USD 6.16USD 184,800SEC filing ↗
2026-07-31ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock36,303USD 4.94USD 179,348SEC filing ↗
2026-07-30ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock272,850USD 4.93USD 1,344,886SEC filing ↗
Show recent Form 4 evidence (6 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-10Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.; Ren Jinsheng; Simcere Pharmaceutical Group Ltd; Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Zaiming, Inc.; Tang RenhongSale (S)Common Stock30,000USD 6.16USD 184,800SEC filing ↗
2026-07-31ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock36,303USD 4.94USD 179,348SEC filing ↗
2026-07-30ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock272,850USD 4.93USD 1,344,886SEC filing ↗
2026-07-29ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock3,410USD 5.00USD 17,050SEC filing ↗
2026-07-28ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock6,400USD 4.95USD 31,680SEC filing ↗
2026-07-27ADAR1 Capital Management, LLC; Schneeberger DanielPurchase (P)Common Stock7,798USD 5.00USD 38,990SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerNXTC
CIK0001661059
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history14 transaction lines from 2020-07-14 to 2026-08-10
12 P purchase lines · 1 S sale lines · 1 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.